Prevalence of PALB2 pathogenic variants is higher in familial and/or hereditary BC cases, varying from 0.36% in a French cohort to 4.8% in Finnish patients; the high index observed in Finland is attributed to the c.1592delT founder mutation [31,32]. The gene discussed is PALB2; the disease is breast cancer.